Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma
Rahul Kumar, Kyle S Smith, Maximilian Deng, Colt Terhune, Giles W Robinson, Brent A Orr, Anthony P Y Liu, Tong Lin, Catherine A Billups, Murali Chintagumpala, Daniel C Bowers, Timothy E Hassall, Jordan R Hansford, Dong Anh Khuong-Quang, John R Crawford, Anne E Bendel, Sridharan Gururangan, Kristin Schroeder, Eric Bouffet, Ute Bartels, Michael J Fisher, Richard Cohn, Sonia Partap, Stewart J Kellie, Geoffrey McCowage, Arnold C Paulino, Stefan Rutkowski, Gudrun Fleischhack, Girish Dhall, Laura J Klesse, Sarah Leary, Javad Nazarian, Marcel Kool, Pieter Wesseling, Marina Ryzhova, Olga Zheludkova, Andrey V Golanov, Roger E McLendon, Roger J Packer, Christopher Dunham, Juliette Hukin, Maryam Fouladi, Claudia C Faria, Jose Pimentel, Andrew W Walter, Nada Jabado, Yoon-Jae Cho, Sebastien Perreault, Sidney E Croul, Michal Zapotocky, Cynthia Hawkins, Uri Tabori, Michael D Taylor, Stefan M Pfister, Paul Klimo Jr, Frederick A Boop, David W Ellison, Thomas E Merchant, Arzu Onar-Thomas, Andrey Korshunov, David T W Jones, Amar Gajjar, Vijay Ramaswamy, Paul A Northcott, Rahul Kumar, Kyle S Smith, Maximilian Deng, Colt Terhune, Giles W Robinson, Brent A Orr, Anthony P Y Liu, Tong Lin, Catherine A Billups, Murali Chintagumpala, Daniel C Bowers, Timothy E Hassall, Jordan R Hansford, Dong Anh Khuong-Quang, John R Crawford, Anne E Bendel, Sridharan Gururangan, Kristin Schroeder, Eric Bouffet, Ute Bartels, Michael J Fisher, Richard Cohn, Sonia Partap, Stewart J Kellie, Geoffrey McCowage, Arnold C Paulino, Stefan Rutkowski, Gudrun Fleischhack, Girish Dhall, Laura J Klesse, Sarah Leary, Javad Nazarian, Marcel Kool, Pieter Wesseling, Marina Ryzhova, Olga Zheludkova, Andrey V Golanov, Roger E McLendon, Roger J Packer, Christopher Dunham, Juliette Hukin, Maryam Fouladi, Claudia C Faria, Jose Pimentel, Andrew W Walter, Nada Jabado, Yoon-Jae Cho, Sebastien Perreault, Sidney E Croul, Michal Zapotocky, Cynthia Hawkins, Uri Tabori, Michael D Taylor, Stefan M Pfister, Paul Klimo Jr, Frederick A Boop, David W Ellison, Thomas E Merchant, Arzu Onar-Thomas, Andrey Korshunov, David T W Jones, Amar Gajjar, Vijay Ramaswamy, Paul A Northcott
Abstract
Purpose: We sought to investigate clinical outcomes of relapsed medulloblastoma and to compare molecular features between patient-matched diagnostic and relapsed tumors.
Methods: Children and infants enrolled on either SJMB03 (NCT00085202) or SJYC07 (NCT00602667) trials who experienced medulloblastoma relapse were analyzed for clinical outcomes, including anatomic and temporal patterns of relapse and postrelapse survival. A largely independent, paired molecular cohort was analyzed by DNA methylation array and next-generation sequencing.
Results: A total of 72 of 329 (22%) SJMB03 and 52 of 79 (66%) SJYC07 patients experienced relapse with significant representation of Group 3 and wingless tumors. Although most patients exhibited some distal disease (79%), 38% of patients with sonic hedgehog tumors experienced isolated local relapse. Time to relapse and postrelapse survival varied by molecular subgroup with longer latencies for patients with Group 4 tumors. Postrelapse radiation therapy among previously nonirradiated SJYC07 patients was associated with long-term survival. Reirradiation was only temporizing for SJMB03 patients. Among 127 patients with patient-matched tumor pairs, 9 (7%) experienced subsequent nonmedulloblastoma CNS malignancies. Subgroup (96%) and subtype (80%) stabilities were largely maintained among the remainder. Rare subgroup divergence was observed from Group 4 to Group 3 tumors, which is coincident with genetic alterations involving MYC, MYCN, and FBXW7. Subgroup-specific patterns of alteration were identified for driver genes and chromosome arms.
Conclusion: Clinical behavior of relapsed medulloblastoma must be contextualized in terms of up-front therapies and molecular classifications. Group 4 tumors exhibit slower biological progression. Utility of radiation at relapse is dependent on patient age and prior treatments. Degree and patterns of molecular conservation at relapse vary by subgroup. Relapse tissue enables verification of molecular targets and identification of occult secondary malignancies.
Figures
References
- Curtin SC, Minino AM, Anderson RN: Declines in cancer death rates among children and adolescents in the United States, 1999-2014. NCHS Data Brief:1-8, 2016
- Ostrom QT Cioffi G Gittleman H, et al. : CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro Oncol 21:v1-v100, 2019
- Gajjar A Chintagumpala M Ashley D, et al. : Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): Long-term results from a prospective, multicentre trial. Lancet Oncol 7:813-820, 2006
- Tarbell NJ Friedman H Polkinghorn WR, et al. : High-risk medulloblastoma: A pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031). J Clin Oncol 31:2936-2941, 2013
- Johnston DL Keene D Strother D, et al. : Survival following tumor recurrence in children with medulloblastoma. J Pediatr Hematol Oncol 40:e159-e163, 2018
- Sabel M Fleischhack G Tippelt S, et al. : Relapse patterns and outcome after relapse in standard risk medulloblastoma: A report from the HIT-SIOP-PNET4 study. J Neurooncol 129:515-524, 2016
- Koschmann C Bloom K Upadhyaya S, et al. : Survival after relapse of medulloblastoma. J Pediatr Hematol Oncol 38:269-273, 2016
- Gajjar A Mulhern RK Heideman RL, et al. : Medulloblastoma in very young children: Outcome of definitive craniospinal irradiation following incomplete response to chemotherapy. J Clin Oncol 12:1212-1216, 1994
- Valteau-Couanet D Fillipini B Benhamou E, et al. : High-dose busulfan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously irradiated medulloblastoma patients: High toxicity and lack of efficacy. Bone Marrow Transplant 36:939-945, 2005
- Grill J Geoerger B Gesner L, et al. : Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: A joint ITCC and SIOPE brain tumor study. Neuro Oncol 15:1236-1243, 2013
- Gururangan S Krauser J Watral MA, et al. : Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma. Neuro Oncol 10:745-751, 2008
- Taylor MD Northcott PA Korshunov A, et al. : Molecular subgroups of medulloblastoma: The current consensus. Acta Neuropathol 123:465-472, 2012
- Ramaswamy V Remke M Bouffet E, et al. : Recurrence patterns across medulloblastoma subgroups: An integrated clinical and molecular analysis. Lancet Oncol 14:1200-1207, 2013
- Morrissy AS Garzia L Shih DJ, et al. : Divergent clonal selection dominates medulloblastoma at recurrence. Nature 529:351-357, 2016
- Hill RM Kuijper S Lindsey JC, et al. : Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease. Cancer Cell 27:72-84, 2015
- Korshunov A Okonechnikov K Sahm F, et al. : Molecular progression of SHH-activated medulloblastomas. Acta Neuropathol 138:327-330, 2019
- Salloum R Chen Y Yasui Y, et al. : Late morbidity and mortality among medulloblastoma survivors diagnosed across three decades: A report from the childhood cancer survivor study. J Clin Oncol 37:731-740, 2019
- Capper D Jones DTW Sill M, et al. : DNA methylation-based classification of central nervous system tumours. Nature 555:469-474, 2018
- Northcott PA Buchhalter I Morrissy AS, et al. : The whole-genome landscape of medulloblastoma subtypes. Nature 547:311-317, 2017
- Cavalli FMG Remke M Rampasek L, et al. : Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell 31:737-754.e6, 2017
- Schwalbe EC Lindsey JC Nakjang S, et al. : Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: A cohort study. Lancet Oncol 18:958-971, 2017
- Sharma T Schwalbe EC Williamson D, et al. : Second-generation molecular subgrouping of medulloblastoma: An international meta-analysis of group 3 and group 4 subtypes. Acta Neuropathol 138:309-326, 2019
- Robinson GW Rudneva VA Buchhalter I, et al. : Risk-adapted therapy for young children with medulloblastoma (SJYC07): Therapeutic and molecular outcomes from a multicentre, phase 2 trial. Lancet Oncol 19:768-784, 2018
- Gajjar A Robinson GW Smith KS, et al. : Outcomes by clinical and molecular features in children with medulloblastoma treated with risk-adapted therapy: Results of an international phase III trial (SJMB03). J Clin Oncol 39:822-835, 2021
- The St Jude Cloud .
- Dunkel IJ Gardner SL Garvin JH Jr, et al. : High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma. Neuro Oncol 12:297-303, 2010
- Kameda-Smith MM Wang A Abdulhadi N, et al. : Salvage therapy for childhood medulloblastoma: A single center experience. Can J Neurol Sci 46:403-414, 2019
- Pickles JC, Stone TJ, Jacques TS: Methylation-based algorithms for diagnosis: Experience from neuro-oncology. J Pathol 250:510-517, 2020
- Balter-Seri J Mor C Shuper A, et al. : Cure of recurrent medulloblastoma: The contribution of surgical resection at relapse. Cancer 79:1241-1247, 1997
- Phi JH Park AK Lee S, et al. : Genomic analysis reveals secondary glioblastoma after radiotherapy in a subset of recurrent medulloblastomas. Acta Neuropathol 135:939-953, 2018
Source: PubMed